Last year the company raised $55 million to advance the development of DYN101 and other nucleic-acid based drugs.
— Reflexion Health’s digital therapy platform has received the OK from the FDA for use by patients looking to rehabilitate their trunk and upper extremities.
Reflexion’s Virtual Exercise Rehabilitation Assistant (VERA) was previously cleared only for lower extremity use. The healthtech company’s VERA can measure, analyze, and records patients’ movements at home as they do rehabilitation exercises without the need for patients to wear any monitoring devices.
Reflexion has launched its trunk module, which it says is meant for a range of applications, including patients who are recovering from spine surgery and those with lower back pain. It plans to launch its module for upper extremities later this year.
The company, a sister company to Boston’s The Learning Corp, is owned by Digital Health Corp.
— Poseida Therapeutics says Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program, will help it manage the collection, transport and delivery of cellular material as it develops its autologous CAR-T programs.
The company said that its collaboration with Be The Match BioTherapies will allow it to benefit from the organization’s experience in collection network management and supply chain and logistics, and to expand its network of apheresis centers—the places where material is collected from patients.
Poseida this year plans to start a Phase 2 trial of one its programs, for patients with multiple myeloma, and ask the FDA for permission to test another of its experimental drugs in patients with prostate cancer.
